BUZZ-Australia's Proteomics climbs on US patent for endometriosis test

** Shares of Proteomics International Laboratories PIQ.AX climb as much as 41.9% to A$0.22, their biggest intraday pct rise since early-April 2020

** The medical technology firm announces the United States Patent and Trademark Office (USPTO) has granted a new patent for the PromarkerEndo proprietary blood test for the diagnosis of endometriosis

** Adds that patent supports commercialisation efforts and underpins the commercialisation pathway, enabling future partnerships and licensing opportunities

** About 1.4 million shares change hands, 2.6 times the 30-day avg

** Proteomics stock down ~72%, YTD


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.